Omega-3 Fatty Acids and Atrial Fibrillation: Current Evidence and Expert Opinion

Clicks: 5
ID: 337872
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #284 of 288 articles by views in european journal of preventive cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 288 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Recent clinical trials have reported an increased risk for atrial fibrillation (AF) in individuals treated with omega-3 fatty acids (FA). As virtually all these studies were conducted with pharmaceutical omega-3 FA preparations in populations at higher risk for cardiovascular disease (CVD), it is unclear to what extent these findings apply to the general population consuming omega-3 FA either from oily fish or from omega-3 FA supplements. Based on an updated meta-analysis reviewed here, consumption of up to 1500 mg/day (and possibly 2400 mg/day) of eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) from food or dietary supplements in the general adult population does not appear to significantly increase risk for AF. Indeed, the preponderance of the evidence suggests that chronic intakes in this range are associated with lower risk for AF (and other CVD outcomes) in the general population. For individuals at high risk for CVD, treatment with EPA+DHA doses of >1500 mg/day might increase the absolute risk for AF (by <1%) and the relative risk (by ∼43%). Because of the favorable effects of EPA+DHA on CVD (and other health) outcomes, our view is that, for the general population, intakes of EPA+DHA afford several health benefits and do not meaningfully increase the risk for AF. For patients with prevalent CVD or at high risk for CVD, the risk-benefit ratio for EPA+DHA intake is favorable, especially for intakes up to 1500 mg/day, but also at higher doses where there may be increased risk for AF.
Reference Key
openalex_W7225010427 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors William Stephen Harris, Raffaele De Caterina, Stanley Nattel, James D Richards, Szabolcs Péter, Carl J. Lavie
Are you one of these authors? Claim your profile
Journal european journal of preventive cardiology
Year 2026
DOI
10.1093/eurjpc/zwag577
URL
https://doi.org/10.1093/eurjpc/zwag577
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.